Critical risk assessment report: use of UK plasma for the manufacture of immunoglobulins and vCJD risk

The Commission on Human Medicines has concluded that the risk of vCJD from the use of UK plasma in immunoglobulin medicinal products would be negligible and that UK-sourced plasma is acceptably safe for the manufacture of these products.

Source:

Medicines and Healthcare products Regulatory Agency